Trial Site Detail

 

Drug:
CS-1008 and Imatinib or Sunitinib
Trial:
A Pilot Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5, Alone or In Combination with Imatinib Mesylate or Sunitinib Malate In Subjects with Advanced Gastrointestinal Stromal Tumors
Conditions: Gastrointestinal Stromal Tumor
Trial Status:
Withdrawn

 

Fox Chase Cancer Center

333 Cottman Ave     
Philadelphia , PA 19111
USA

 

Principal Investigator:
Margeret von Mehren, M.D.
Contact:
1-888-FOX-CHASE
Activation Status of this Site:
Closed
Notes about this Site:
Fox Chase Cancer Center Website:
https://www.protonet.fccc.edu/fccc/pims/

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.